Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322438 · ClinicalTrials.gov registry record · Phase 1
Effect of Rifampin on the Pharmacokinetics of BAY73-4506
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01322438 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 24 participants.
The verdict
NCT01322438, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
Interventions
- DRUG Regorafenib (BAY73-4506) + rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01322438
The ClinicalTrials.gov registry entry for NCT01322438 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Regorafenib (BAY73-4506) + rifampin is the first listed.
NCT01322438 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01322438 about?
NCT01322438 is a clinical study titled "Effect of Rifampin on the Pharmacokinetics of BAY73-4506". The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
What is the current status of trial NCT01322438?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2011-03. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01322438?
The interventions under investigation include: Regorafenib (BAY73-4506) + rifampin (DRUG).
Who is sponsoring clinical trial NCT01322438?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.